BioCentury
ARTICLE | Product Development

Novavax data sets benchmark for protein vaccines, bolsters South African variant’s status as bigger risk to first-wave products

January 29, 2021 3:26 AM UTC

Novavax’s efficacy readout suggests protein vaccines against SARS-CoV-2 could rival leading modality mRNA, and provides more evidence that among the two most watched viral variants, the South African strain poses the bigger resistance threat for front-runner vaccines and therapies.

On Thursday, Novavax Inc. (NASDAQ:NVAX) announced its COVID-19 vaccine candidate NVX-CoV2373 showed 89.3% efficacy in a Phase III trial in the U.K. ...

BCIQ Company Profiles

Novavax Inc.